ISHLT: Derivation of a Bayesian Network Model from an Existing Risk Score Calculator for Pulmonary Arterial Hypertension

Purpose: We propose an alternative approach to the extensively validated REVEAL risk score calculator using Bayesian network (BN) modeling. We derived a BN model with the same variables and discretization cut points as the REVEAL risk score calculator and data from the REVEAL registry. This study compared the performance and relative impact of the variables […]

Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it

Authors: Raymond L. Benza MD, Lisa Carey Lohmueller, Jidapa Kraisangka, Manreet Kanwar MD Pulmonary arterial hypertension (PAH) is a chronic and rapidly progressive disease that is characterized by extensive narrowing of the pulmonary vasculature, leading to increases in pulmonary vascular resistance, subsequent right ventricular dysfunction, and eventual death. There are currently multiple approved drugs—developed as single or combination […]

Collaboration: Bayer

We are pleased to announce that Bayer is collaborating with us on PHORA. Bayer data experts will incorporate recent clinical trials such as PATENT 1 and PATENT 2 in the PHORA predictive models.

Collaboration: Actelion Pharmaceuticals

We are pleased to announce that Acetlion is collaborating with us on PHORA. Actelion data experts will incorporate recent clinical trials such as  REVEAL & REVEAL 2.0, EARLY, BREATH, SERAPHIN and GRIPHON in the PHORA predictive models.

Collaboration: United Therapeutics

We are pleased to announce that United Therapeutics is collaborating with us on PHORA. United Therapeutics data experts will incorporate recent clinical trials such as TRIUMPH and SC Treprostinil data in the PHORA predictive models.

Collaboration: FDA

Welcome Christine Garnett! We are pleased Christine is joining our data science experts in developing the PHORA Bayesian models.